2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1554 Effective and safe bridging-to-transplant induction with CD7 CAR T-cell therapy in multi-line chemotherapy-refractory pediatric T-ALL

Ning Wang, Lipeng Liu2, Junxia Wang3, Fang Liu4, Xiaofan Zhu, MD5, Wenyu Yang6
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Pediatric T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) accounts for approximately 10-15% of childhood ALL cases and is characterized by aggressive clinical behavior and frequent extramedullary involvement. For children who have failed two or more salvage chemotherapy lines, therapeutic options become exceptionally limited, and conventional reinduction attempts yield response rates below 20% in most real-world reports. CD7, a type I transmembrane glycoprotein expressed on more than 90% of T-ALL/LBL blasts and on normal T and NK cells, has emerged as a promising target for chimeric antigen receptor (CAR) T-cell therapy. Early-phase clinical trials have demonstrated substantial anti-leukemic activity, yet the optimal integration of CD7 CAR T-cells into the treatment algorithm for multi-line refractory pediatric patients, particularly as a bridge to hematopoietic stem cell transplantation (HSCT), remains undefined. Moreover, robust prognostic biomarkers that can guide patient selection and timing of intervention are urgently needed.

Purpose: This real-world study aims to evaluate the induction efficacy, safety, and transplantation-bridging potential of CD7 CAR T-cell therapy in pediatric R/R T-ALL/LBL refractory to multiple chemotherapy lines, and to identify independent predictors of treatment response.

Methods: This single-center retrospective study included 57 pediatric patients with R/R T-ALL/LBL who received reinduction chemotherapy and had evaluable efficacy data. The primary endpoint was the overall response rate (ORR), the cumulative incidence of response (CIR), event-free survival (EFS), and overall survival (OS) was presented and risk factors were evaluated by Firth penalized logistic regression. Safety profiles, such as cytokine release syndrome (CRS) and neurotoxicity, were also documented.

Results: After the initial reinduction chemotherapy, only 19 patients (33.3%) achieved complete remission (CR), confirming the highly chemorefractory nature of this cohort. After induction, 27 patients with non-remission (NR) disease received CD7 CAR T-cell therapy, while 12 NR patients still received subsequent chemotherapy. After induction failure, the CAR-T group showed a significantly higher response rate than those who still received subsequent chemotherapy (77.8% vs. 16.7%, P< 0.001; RR = 4.67, 95% CI 1.30–16.80).  Firth univariable regression analysis revealed that MRD >25%, and pre-infusion extramedullary involvement combined with high-risk mutations were significantly associated with a lower CR rate (all p<0.05). On multivariable Firth regression, only MRD >25% remained an independent prognostic factor (OR = 0.041, 95% CI 0.0003-0.479, P=0.007), underscoring that pre-treatment tumor burden is the dominant barrier to CAR T-cell efficacy. Among 57 patients, altogether 10 patients in the chemotherapy group and 14 patients in the CAR-T group received hematopoietic stem cell transplantation (HSCT). The non-relapse mortality (NRM) in the CAR-T and chemotherapy groups was 7.7% vs 11.1%, and the cumulative incidence of relapse (CIR) did not differ significantly between the two groups (all P>0.05), suggesting that post-relapse salvage therapies were effective in the CAR-T arm. Common adverse events included cytokine release syndrome (CRS) in 74.1% (20/27) of patients, with grade 1 in 10 patients, grade 2 in 6, and grade 3 in 4. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in one patient (3.7%), which was grade 1. No CAR-T infusion-related death was observed.

Conclusion: Pediatric R/R T-ALL/LBL has a dismal prognosis, and those who fail initial chemotherapy have extremely low remission rates with subsequent chemotherapy. CD7 CAR-T cell therapy is a safe and effective option for remission induction, particularly in patients with pre-infusion MRD <25%. These findings strongly support the incorporation of CD7 CAR T-cells into the standard treatment algorithm for high-risk, chemotherapy-refractory pediatric T-ALL/LBL. The outcomes of bridging transplantation after CAR-T-induced remission were comparable to those after chemotherapy-induced remission, supporting CAR-T as a promising bridge to transplantation. Nonetheless, given the inherent limitations of a single-center retrospective design and the modest sample size, our results should be interpreted with caution; these findings require validation in prospective studies with larger cohorts.

Ning Wang: No relevant conflicts of interest to declare.